Nota de prensa


• €23m [US$25.5m] equity provided mainly by US-based Cowen Healthcare Investments
• €24m [US$26.5m] finance facility provided by the European Investment Bank (EIB)
• Increased funding allows for finalization of all Marketing Authorization Application preparation activities
• Ysios Capital participated in the initial funding of €116M raised in July 2019

AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP), today announces that it has raised additional funds of €47m [US$52m], increasing the total recent fundraising to €163m [US$176m].

This new capital will be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI). It also allows the Company to fund the steps required to submit Marketing Authorization Applications following the trial’s completion, including CMC validation and commercial manufacture.

€23m has been mainly provided by Cowen Healthcare Investments, an affiliate of Cowen Inc., which joins the existing investor syndicate of LSP and Andera Partners, Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare that raised an initial €116m in July 2019.

The additional €24m has been provided by the European Investment Bank (EIB), under the “Infectious Diseases Finance Facility” (IDFF) of the InnovFin – EU-Finance for Innovators program, which is financed from the EU’s research and innovation program, Horizon 2020.

AKI is a devastating disease, with a high mortality rate which affects millions of patients worldwide and has no approved pharmacological treatments. The most important cause of AKI is sepsis.1,2 AM-Pharma was awarded Fast Track designation by the US Food and Drug Administration in 2016 and recAP has the potential to be a first-in-class medicine for SA-AKI. The Phase III trial in reCAP will be the largest clinical trial in SA-AKI, seeking to enroll up to 1,400 patients with SA-AKI at sites in approximately 12 countries.

Erik van den Berg, AM-Pharma’s CEO commented: “This additional capital adds to the financing in July 2019, with the addition of the respected Cowen Healthcare Investments team to our international investor syndicate and support from the EIB. The Cowen team not only provides additional funds but also vast experience that can be drawn upon. We are also delighted with the award of funds from the EIB which is a great supporter of innovative medicines and will enable the building of our company.”

He added, “The funds raised for our recAP Phase III trial is now at €163m which will also support further marketing application readiness activities. The support from our shareholders and the EIB highlights the urgent medical need in SA-AKI and recAP’s potential to treat this indication. We look forward to working with our expanded investor syndicate and continuing work on recAP’s path to market.”

Tim Anderson at Cowen added “AM-Pharma has completed a robust 301 patient Phase II trial in SA-AKI, following a clear path based on regulatory feedback and the team has significant expertise in the field of acute kidney injury. We believe that recAP has the potential to be an important treatment option for AKI and other indications of high unmet medical need. We look forward to working with the team and the rest of the investors throughout the Phase III trial and beyond.”

About Ysios Capital

Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. We target the biotechnology industry, with an exclusive focus on therapeutics. Founded in 2008, Ysios Capital has € 191,4 million in assets under management through three funds: Ysios BioFund I (€65 M), Ysios BioFund II Innvierte (€ 126M) and Ysios BioFund III, currently fundraising.

Nuevos informes y series de datos: El Capital riesgo Informal en España 2019 /  Informe de Impacto Económico y Social del Capital Privado en las operaciones de Middle Market en España. 2018 (ASCRI) / Informe de Impacto Económico y Social de los préstamos otorgados por Enisa

Otros informes destacados: Madurez del Venture Capital en España. Hechos relevantes y detalle de más de 60 casos de éxito desde los años 90 hasta la actualidad… Also in english / Financiación de startups de Energía en España / El Préstamo Participativo como herramienta para el arranque de empresas en España / El tiempo de las desinversiones en Private Equity en España (Also in english)

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos requeridos están marcados *

Publicar comentario